Michael P. Isles. (2022). Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety. Frontiers Media S.A..
Chicago Style (17th ed.) CitationMichael P. Isles. Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationMichael P. Isles. Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.